이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

다발성 골수종에서의 18F-플루시클로빈 PET/CT

2026년 10월 28일 업데이트: National Cancer Institute (NCI)

다발성 골수종에서 18F-플루시클로빈 PET/CT를 평가하는 제2상 시험

Background:

Multiple myeloma (MM) is an incurable cancer of certain blood cells. MM often returns after treatment, and most people survive only 5 to 8 years after diagnosis. To improve survival, researchers need to find ways to identify returning disease earlier.

Objective:

To find out if the radiotracer 18F-fluciclovine (a substance injected into the blood during imaging scans) is better at detecting MM than the one (18F-FDG) currently used for this purpose.

Eligibility:

Adults aged 18 years or older with MM. The MM may be newly diagnosed (NDMM); or it may have returned or failed to respond after at least 1 prior line of treatment (RRMM).

Design:

Participants will be screened. They will have blood tests. They will have a positron emission tomography (PET) or computed tomography (CT) scan using 18F-FDG. The radiotracer will be injected into a vein. Then participants will lie on a table while the PET/CT scan takes images of their body.

All participants will have 3 study visits. During each visit they will have:

Two PET/CT scans. One with 18F-FDG, one with 18F-fluciclovine.

An optional magnetic resonance imaging scan.

A bone marrow biopsy. An area on the hip will be numbed; a needle will be inserted to draw out a sample of the soft tissue from inside the bone.

These tests may be spread over 30 days for each visit.

NDMM participants will have their second study visit 2 to 4 weeks after they complete their usual treatment for the disease. RRMM participants will have their second visit 6 months after their first.

All participants will have a third study visit after 5 years or when their disease progresses.

연구 개요

상세 설명

Background:

  • Multiple myeloma (MM) is an incurable malignancy of plasma cells that leads to destructive bone lesions, renal damage, anemia, and hypercalcemia. MM is the second most common hematologic malignancy. The American Cancer Society estimates that annually over 34,000 new cases of MM will occur in the U.S. and over 12,000 deaths due to MM in 2022.
  • Overall survival (OS) has improved significantly over the past 20 years with the development of proteasome inhibitors (PIs), immunomodulatory agents (IMiDs) and anti-CD38 monoclonal antibodies. However, despite these advances, patients ultimately relapse requiring multiple subsequent lines of therapy. As MM evolves, it generally becomes more refractory, and patients ultimately succumb to their disease.
  • With multiple lines of efficacious therapies, the correct early identification of relapsed disease is important to trigger initiation of a new line of therapy.
  • Limitations in conventional imaging highlight a need for molecular imaging agents with better sensitivity for detecting and measuring tumor burden to improve staging and treatment selection for patients with MM and plasma cell dyscrasias.
  • 18F-fluciclovine is a radionuclide approved by the FDA for evaluating suspected prostate cancer recurrence but has shown additional ability in detecting MM lesions.

Objective:

To determine the concordance between 18F-fluciclovine PET/CT and 18F-FDG PET/CT in participants with multiple myeloma

Eligibility:

  • Participants >= 18 years old

  • Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2

  • Participants must have a documented diagnosis of MM defined by the International Myeloma Working Group (IMWG) Criteria

  • Participants fit criteria for one of the following categories:

    • Newly diagnosed multiple myeloma (NDMM) without previous treatment (or within the first 3 cycles of front-line treatment)
    • Relapsed and/or Refractory multiple myeloma (RRMM) with at least 1 prior line of therapy

Design:

This is an open-label, single center phase 2 study evaluating 18F-fluciclovine PET/CT imaging in up to 50 participants with multiple myeloma. Participants will be enrolled into one of two cohorts based on disease status; newly diagnosed multiple myeloma (NDMM) participants will be enrolled into Cohort 1 and relapsed refractory multiple myeloma (RRMM) participants will be enrolled into Cohort 2. All subjects will undergo an 18F-fluciclovine injection followed by a static whole-body PET/CT at three time points: Timepoint #1, Timepoint #2 (after induction for NDMM or at 6 months for RRMM) and Timepoint #3 (at progression or at 5 years). Results will be compared to 18F-FDG PET/CT imaging at those same timepoints.

연구 유형

중재적

등록 (추정된)

60

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

연구 장소

    • Maryland
      • Bethesda, Maryland, 미국, 20892
        • 모병
        • National Institutes of Health Clinical Center
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

  • INCLUSION CRITERIA:

  • Participants must have a documented diagnosis of MM defined by the IMWG Criteria. Participants at diagnosis must have had a serum M-protein >= 3 g/dL and/or bone marrow plasma cells >= 10% and at least one of the following:

    • Anemia: Hemoglobin <=10 g/dL, or
    • Renal Failure: serum creatinine >= 2.0 mg/dL, or
    • Hypercalcemia: Ca >= 10.5 mg/dL, or
    • Lytic bone lesions on X-ray, CT, or PET/CT, or
    • >= 2 focal lesions on spinal MRI, or
    • >= 60% bone marrow plasma cells, or
    • Involved/un-involved serum free light chain ration >= 100
  • Participants must have measurable disease defined by any one of the following:

    • Monoclonal bone marrow plasma cells > 5%
    • Serum monoclonal protein >= 0.2 g/dl
    • Urine monoclonal protein > 200 mg/24 hr
    • Serum immunoglobulin free light chain > 10 mg/dL AND abnormal kappa/lambda ratio
    • A measurable lesion on PET/CT or MRI
  • Participants fit criteria for one of the following categories:

    • Newly diagnosed multiple myeloma (NDMM)
    • Relapsed and/or refractory multiple myeloma (RRMM) with at least 1 prior line of therapy
  • Age >=18 years.

  • ECOG performance status <= 2

  • Negative serum or urine pregnancy test at screening for WOCBP.

  • Women of child-bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control; abstinence) 24 hours prior to and for the 24 hours after each 18F-fluciclovine administration.

  • Ability of subject to understand and the willingness to sign a written informed consent document.

EXCLUSION CRITERIA:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FDG
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-fluciclovine or other similar agents.
  • Subjects with severe claustrophobia unresponsive to oral anxiolytics or unwilling to take them.
  • Uncontrolled intercurrent illness including, psychiatric illness/social situations that would limit compliance with study requirements.
  • Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 18F-fluciclovine, breastfeeding should be discontinued if the mother is treated with 18F-fluciclovine until 3 days after 18F-fluciclovine.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: 18F-fluciclovine PET/CT in Multiple Myeloma

Evaluate 18F-fluciclovine PET/CT in participants with multiple myeloma at Timepoint #1, Timepoint #2 ( after induction treatment (NDMM) or six months (RRMM)) and at Timepoint #3 (the time of progression or 5 years).

370 MBq (10 mCi)(+/-20%) as a bolus intravenous injection.

All participants will undergo 18F-FDG PET/CT within 30 days of the 18F-fluciclovine PET/CT scan

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
To determine the concordance between 18F-fluciclovine PET/CT and 18F-FDG PET/CT in participants with multiple myeloma.
기간: After 50 evaluable participants have completed baseline scans.

The performance of 18F-fluciclovine PET/CT is assessed by concordance with the 18F-FDG PET/CT imaging in scan positivity. A positive lesion is defined as focal uptake greater than background associated with abnormal CT findings (i.e., lytic bone lesions or extramedullary tissue.) The point estimates and 95% confidence intervals of the concordance rate in scan positivity between 18F-fluciclovine and 18F-FDG PET/CT will be reported.

After 50 evaluable participants have completed baseline scans.

2차 결과 측정

결과 측정
측정값 설명
기간
Evaluate the efficacy of 18F-fluciclovine in measuring disease volume as compared to other indicators of disease volume such as serum M protein, serum free-light chains, urine M protein, B2 microglobulin, and bone marrow plasma cell percentage.
기간: Between Timepoint #1 and Timepoint #3

Disease volumes measured by 18F-fluciclovine will be correlated with other indicators of disease volume such as serum M protein, serum free-light chains, urine M protein, B2 microglobulin, and bone marrow plasma cell percentage by Spearman rank correlation.

Between Timepoint #1 and Timepoint #3
Evaluate the ability of 18F-fluciclovine to identify minimal residual disease (MRD) as compared to MRD status determined by bone marrow flow cytometry or next generation sequencing (NGS).
기간: Between Timepoint #1 and Timepoint #3

Status of minimal residual disease (MRD) identified by 18F-fluciclovine will be compared to MRD status determined by bone marrow flow cytometry or next generation sequencing (NGS).

Between Timepoint #1 and Timepoint #3
Evaluate the ability for 18F-fluciclovine to evaluate response after treatment as compared to the IMWG response criteria.
기간: Between Timepoint #1 and Timepoint #3

Response after treatment determined by 18F-fluciclovine will be compared to the IMWG response criteria by McNemar test.

Between Timepoint #1 and Timepoint #3
Evaluate the safety of 18F-fluciclovine as a radiotracer in patients with multiple myeloma.
기간: From the time at each 18F-fluciclovine dose through 3 days after each dose.

All participants will be evaluable for toxicity from the time at each 18F-fluciclovine dose through 3 days after each dose. Safety of the agents will be assessed by determining the type, grade, and frequency of adverse events noted in each participant who receives at least one dose of each of the study treatments. Safety data will be presented in a summary.

From the time at each 18F-fluciclovine dose through 3 days after each dose.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Elizabeth M Hill, M.D., National Cancer Institute (NCI)

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 3월 25일

기본 완료 (추정된)

2027년 12월 6일

연구 완료 (추정된)

2032년 12월 6일

연구 등록 날짜

최초 제출

2023년 10월 26일

QC 기준을 충족하는 최초 제출

2023년 10월 26일

처음 게시됨 (실제)

2023년 10월 27일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 29일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 10월 28일

마지막으로 확인됨

2026년 10월 13일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

All collected IPD will be shared. In addition, all large scale genomic sequencing data will be shared with subscribers to dbGaP.

IPD 공유 기간

Clinical data will be made available during the study and indefinitely. Genomic data are available once genomic data are uploaded per protocol GDS plan for as long as database is active.

IPD 공유 액세스 기준

Clinical data will be made available upon request and with the permission of the study PI. Genomic data are made available via dbGAP through requests to the data custodians.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다